Melanoma can metastasize at an early stage, and these metastases are typically resistant to medical treatment. In addition, melanoma is rising in incidence and mortality, greatly increasing the need for methods of prevention and treatment. Evidence suggests that chemokines and their receptors are important regulators of tumor immunity, progression, metastasis, and, angiogenesis in many cancers, including melanoma. The activities of chemokines and their receptors have been shown to be altered by polymorphisms but the impact of these changes on melanoma remains to be elucidated. Preliminary work has identified a polymorphism of a single chemokine receptor that influences the risk of melanoma, but as yet no comprehensive investigations of links between melanoma and chemokine or chemokine receptor polymorphisms have been performed. We propose to detail inherited variations in chemokines and their receptors and determine their associations with melanoma risk, survival, and NRAS and BRAF mutational subtypes in the large international population-based Genes, Environment, and Melanoma (GEM) study. We will also determine whether these relationships are modified by age, ultraviolet exposure, phenotypic traits, and polymorphisms in other genes. Few previous studies have simultaneously addressed the 'immunogenicity'of melanoma along with the oncogenic pathways. The results are likely to improve risk prediction and evidence-based recommendations for environmental protection and enable better outcomes prediction and customization of treatment paradigms for affected patients.
The objective of this competitive renewal is to determine whether inherited variants of chemokines and their receptors, which are key modulators of tumor immunity, are associated with melanoma risk, survival, and tumor mutations in melanoma, with a particular focus on covariates of risk: age and ultraviolet radiation. The work will be done in the context of a large international population-based study of over 3,000 melanoma patients. The results should lead to better risk prediction and more evidence-based recommendations for environmental protection and enable better survival prediction and the identification of patient groups most likely to benefit from targeted therapies for melanoma treatment.
|Taylor, Nicholas J; Reiner, Anne S; Begg, Colin B et al. (2015) Inherited variation at MC1R and ASIP and association with melanoma-specific survival. Int J Cancer 136:2659-67|
|Thomas, Nancy E; Kricker, Anne; Waxweiler, Weston T et al. (2014) Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol 150:1306-314|
|Vuong, Kylie; McGeechan, Kevin; Armstrong, Bruce K et al. (2014) Occupational sun exposure and risk of melanoma according to anatomical site. Int J Cancer 134:2735-41|
|Berwick, Marianne; Reiner, Anne S; Paine, Susan et al. (2014) Sun exposure and melanoma survival: a GEM study. Cancer Epidemiol Biomarkers Prev 23:2145-52|
|Berwick, Marianne; MacArthur, Jamie; Orlow, Irene et al. (2014) MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res 27:485-8|
|Thomas, Nancy E; Slater, Nathaniel A; Edmiston, Sharon N et al. (2014) DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. Pigment Cell Melanoma Res 27:1097-105|
|Pearlstein, Michelle V; Zedek, Daniel C; Ollila, David W et al. (2014) Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol 41:724-32|
|Nikolaishvilli-Feinberg, Nana; Cohen, Stephanie M; Midkiff, Bentley et al. (2014) Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. J Histochem Cytochem 62:185-96|
|Kricker, Anne; Armstrong, Bruce K; Goumas, Chris et al. (2013) Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol 149:921-7|
|Raskin, Leon; Fullen, Douglas R; Giordano, Thomas J et al. (2013) Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. J Invest Dermatol 133:2585-92|
Showing the most recent 10 out of 35 publications